Navigation Links
Breast cancer subtypes linked to survival from secondary brain tumors
Date:2/27/2008

Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. A study published in the open access journal Breast Cancer Research shows that patients with tumours that are negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor-2 (HER2) or that are HER2+/ER- appear to be most at risk from developing brain metastases. Survival is also correlated to the triple receptor status.

This is the first time that researchers have documented a possible link between breast cancer subtypes and the incidence and prognosis of brain metastases, which occur in up to one third of metastatic breast cancer patients.

A team from the National Cancer Centre in the Republic of Korea analysed data from 126 patients with brain metastases from a pool of 805 patients diagnosed with metastatic breast cancer and treated at the Centre. The presence or absence of ER, PR and HER2 were tested by immunohistochemical staining and/or fluorescent in situ hybridisation.

More than half of the patients with early (non-metastatic) breast cancer were of the luminal A subtype (ER or PR+ and HER2-). The proportion of patients with HER2+/ER- or triple-negative tumours was significantly higher among patients with brain metastases compared to the early breast cancer population, suggesting that these latter two subtypes were associated with the development of brain metastases.

The analysis also showed a correlation between the survival of patients and their triple receptor subtypes following the diagnosis of brain metastases, the survival time of which is just 3 6 months. Patients with luminal A (4.0 months) and triple-negative tumours (3.4 months) had a similar shorter survival time compared with luminal B (ER or PR+ and HER2+; 9.2 months) and HER2+/ER- (5.0 months) tumours.

Patients with HER2-positive tumours experienced a significant survival benefit if
'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... First Choice Emergency Room , the ... United States, named Richard Daniels, DO the Medical Director ... , “We are pleased to announce that Dr. Daniels ... facility in Pflugerville,” said Dr. James M. Muzzarelli, Executive ... Dr. Daniels received his undergraduate degree from Brigham Young ...
(Date:8/20/2014)... 2014 Kowa Optimed returns after a ... debut the new SL-17 portable slit lamp. , The ... LED source controlled by an illuminated thumb wheel for ... uses commercially available AAA rechargeable and dry cell batteries, ... requiring batteries designed specifically for the device. The new ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3
... , TUESDAY, Oct. 11 (HealthDay News) -- A small, preliminary study ... intestines -- a potential sign that the pills might reduce the ... be done, and the researchers aren,t yet recommending that people head ... meal times. "If you want to add ginger to part ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 11 (HealthDay ... raises the risk for both breast and ovarian cancer are ... new study indicates. Those other women include both women ... of breast and ovarian cancer, and women without ...
... A team of scientists led by a Penn State ... an alternative method of molecular depth profiling -- a ... such as human tissue, nanoparticles, and other substances. In ... modeling to show the effectiveness and limitations of the ...
... is exploring the ethical challenges that clinicians and ... in the United States. The project is supported by ... Program. Most of the estimated 11 million undocumented ... are ineligible for public insurance programs. They are prohibited ...
... intersection density and well-connected streets in towns and cities ... according to a Queen,s University study. "We,ve known ... a high density of intersections in a given areahelps ... and more efficient for them to walk to work ...
... TUESDAY, Oct. 11 (HealthDay News) -- Nearly 90 percent of ... well-being, according to a new national poll of 1,000 voters. ... also revealed that by having routine mammograms, women gain a ... that poll results show that nearly nine in 10 women ...
Cached Medicine News:Health News:Ginger Supplements Might Ease Inflammation Linked to Colon Cancer 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 3Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 4Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 2Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 3Health News:New project examines medical safety net for undocumented patients 2Health News:Women Say Mammograms Give Them Sense of Control: Survey 2
(Date:8/19/2014)... JERUSALEM , August 19, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Intellectual Property Department of ... patent for its invention, titled "Methods and Compositions ... Oramed Pharmaceuticals  Oramed Pharmaceuticals is a ...
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 /PRNewswire/ ... announced today a protocol amendment to allow for expanded dosing ... U.S. Food and Drug Administration (FDA) and that a new ... at three clinical trial sites in the United ... of US$2.9 million have been raised through warrant exercise in ...
(Date:8/19/2014)... ,Weight Loss- Market Analysis, Global API Manufacturers ... insights about phase III pipeline drugs and marketed drugs ... is to establish the understanding for API Manufacturers for ... countries and regions. While the leading brands, companies and ... on the drug master filings across the US, ...
Breaking Medicine Technology:Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4
... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, manufacturer ... announced financial results the third quarter ended September 30, 2009. , , ... ... Q3 2008 ...
... TRIANGLE PARK, N.C., Nov. 12 Chimerix, Inc., ... address life-threatening diseases, announced today that Kenneth I. ... overview at two upcoming investor conferences. Mr. ... pipeline, including CMX001, a broad-spectrum antiviral being developed ...
Cached Medicine Technology:Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 11Chimerix to Present at Two Upcoming Investor Conferences 2
... MJS anatomic knee ... enhance durability, minimize polyethylene ... surfaces, to minimize contact ... and to achieve a ...
Simplified Design-Based on 15 Years of Experience...
... The result of more than a ... is based on a comprehensive study of ... resection, and tibial insert retrieval analysis.,As a ... axial rotation and motion patterns in total ...
... True to its leadership role within ... the clinical experience of the industry's leading ... Platform Knee System, with the clinically proven ... world's leading rotating platform knee. ,The result ...
Medicine Products: